GREY:TBPMQ - Post by User
Comment by
SamV21on Feb 07, 2022 1:41pm
76 Views
Post# 34405526
RE:ARDS-003 is going to be a successful drug
RE:ARDS-003 is going to be a successful drug - Approximately 40+ key companies are developing Sepsis therapies. These companies are Cidara Therapeutics, Vivacelle Bio, Shaperon, Karyopharm Therapeutics, SciClone Pharmaceuticals, Asahi Kasei Pharma, Sanofi, Shionogi, Revimmune, Inotrem, Enlivex Therapeutics, Abionyx, and others have their Sepsis drug candidates in the under different phases of clinical development.
- Rezafungin (formerly known as CD101) is an echinocandin drug, currently in Phase III clinical development for candidemia, invasive candidiasis and prophylaxis of invasive fungal infections due to Candida Aspergillus and Pneumocystis. The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and fast track designations for rezafungin.
- Funny no mention of Tetra Bio Pharma as usual , Tetra has wishfull thinking good luck, left in the dust and paid for it.